FDA says Ozempic shortage is over, chilling boom in off-brand versions
The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
Why Novo Nordisk Stock Popped on Friday
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...
Hims & Hers Health: The Ultimate Pick For The Next Decade
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...
Medscape2d
Any Time Is a Good Time for Growth Hormone Shots
Growth hormone injections can be administered in children with growth disorders at any convenient time for the family as ...
PharmiWeb2d
Hormone Replacement Therapy Market: Comprehensive Analysis (2024-2035)
Market OverviewThe Global Hormone Replacement Therapy Market is valued at USD 22.6 Billion in 2023 and is projected to reach ...
Future Market Insights2d
Global Human Growth Hormone Treatment and Drugs Market Poised for Steady Growth to Reach USD 5.26 Billion by 2033 at a CAGR of 3.7%
The global Human Growth Hormone Treatment and Drugs Market is expected to reach a value of around USD 5.26 billion by 2033, ...
Iconic 60-year-old company that transformed America edges towards oblivion - because of Ozempic
A beloved company that has been part of the fabric of the US and has served hundreds of millions of customers around the ...
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...